Article Text

PDF
High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma
  1. Matti Pukkila1,
  2. Ari Kosunen1,
  3. Kirsi Ropponen2,
  4. Jukka Virtaniemi1,
  5. Jari Kellokoski1,
  6. Eero Kumpulainen3,
  7. Risto Pirinen2,
  8. Juhani Nuutinen1,
  9. Risto Johansson3,
  10. Veli-Matti Kosma2
  1. 1Otorhinolaryngology—Head and Neck Surgery, Institute of Clinical Medicine, University of Kuopio and Kuopio University Hospital, Kuopio, Finland
  2. 2Pathology and Forensic Medicine, Institute of Clinical Medicine, University of Kuopio and Kuopio University Hospital, Kuopio, Finland
  3. 3Institute of Clinical Medicine, University of Kuopio and Kuopio University Hospital, Kuopio, Finland
  1. Correspondence to:
 Dr V-M Kosma
 Pathology and Forensic Medicine, Institute of Clinical Medicine, University of Kuopio, PO Box 1627, 70211 Kuopio, Finland; velimatti.kosma{at}uku.fi

Abstract

Background: Versican, an extracellular matrix proteoglycan, has been noted to be expressed in several malignant tumours and has been suggested to play an important role in cancer development and tumour growth.

Aims: To investigate whether the versican expression level in the peritumoural stromal tissue of primary oral squamous cell carcinoma (OSCC) predicts relapse-free or disease-specific survival. Also, to study the associations between versican expression and several other clinicopathological variables, as well as tumour cell proliferation.

Methods: Immunohistochemistry was used to study the expression of versican and tumour cell proliferative activity in 139 OSCCs. All pertinent clinical data were collected retrospectively from the hospital records.

Results: In this cohort, versican expression did not correlate with the clinicopathological factors or tumour cell proliferation. In univariate analyses, higher risk for disease recurrence was associated with higher stromal versican expression score (p = 0.02), positive neck node status (p = 0.02), lower Karnofsky performance status (p = 0.03) and higher tumour cell proliferation index (p = 0.04). Increased disease-specific risk of death was associated with high stromal versican expression score (p = 0.005) higher T class (p = 0.002), positive neck node status (p<0.001), higher stage (p<0.001), poorer histological differentiation (p = 0.005), worse general condition of the patient (p = 0.049) and increased tumour cell proliferative index (p = 0.02). In multivariate disease-specific survival analysis, high stromal versican expression score (p = 0.048), poorer histological differentiation (p = 0.047) and higher stage (p = 0.002) independently predicted poorer disease outcome.

Conclusions: In this cohort, increased stromal versican expression correlated with both increased risk for disease recurrence and shortened survival. High stromal versican expression may thus be considered an independent and adverse prognostic marker in OSCC.

  • DFS, disease-free survival
  • DSS, disease-specific survival
  • ECM, extracellular matrix
  • OSCC, oral squamous cell carcinoma
  • PBS, phosphate-buffered saline

Statistics from Altmetric.com

Footnotes

  • Published Online First 26 May 2006

  • Funding: This study was financially supported by Kuopio University Hospital EVO Funds, The Savo Cancer Fund and The Finnish Foundation for Cancer Research.

  • Competing interests: None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.